To include your compound in the COVID-19 Resource Center, submit it here.

Remura bromfenac: Phase III data

Top-line data from the double-blind, placebo-controlled, U.S. Phase III WEST trial in 420 patients with dry eye disease showed that both doses of Remura missed the co-primary endpoints of significantly

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE